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Obesity and associated diseases like type 2 diabetes are rapidly growing health concerns 
across the globe. The uptake and expenditure of energy in the body are tightly regulated by a 
plethora of enzymes and hormones in central and peripheral tissues. Skeletal muscle is an 
important organ in this regulatory network and exhibits remarkable flexibility with regard to 
fuel utilization and modulates whole-body glucose and lipid metabolism as underlined by the 
work presented in this thesis.  
The enzyme diacylglycerol kinase (DGK) is involved in lipid signaling and metabolism. 
Ablating the isoform DGKε allowed us to assess its regulatory role in whole-body energy 
metabolism. We observed an enrichment of diacylglycerol lipid species in skeletal muscle of 
high-fat fed DGKε kockout mice which was paradoxically associated with improved glucose 
tolerance. Nonetheless, the loss of DGKε promoted a greater whole-body reliance on lipids as 
fuel source. Taken together, this data identifies DGKε as a modulator of skeletal muscle lipid 
metabolism affecting whole-body energy handling. 
 Signaling of the heterotrimeric AMP-activated protein kinase (AMPK) stimulates ATP-
generating processes when energy levels are low. We characterized the extent to which activity 
of the regulatory AMPK subunit γ1 in skeletal muscle modifies whole-body metabolism by 
expressing the constitutively active transgene AMPKγ1H151R in skeletal muscle. This led to 
increased whole-body insulin sensitivity with a greater reliance on glucose as a fuel source. 
Furthermore, sex-specific effects on adipose tissue were observed. Our findings underline the 
potential therapeutic value of tissue-specific AMPK activation as it may protect against the 
development of insulin resistance. Conversely, the activation of AMPKγ3, another regulatory 
subunit isoform abundant in skeletal muscle, did not affect the whole-body lipid oxidation rate. 
For this assessment, we established an in vivo assay relying on the intravenous administration 
of 3H-palmitic acid combined with non-β-oxidizable 14C-2-bromopalmitic acid. Independently 
of the level of AMPK activation in skeletal muscle, we report an increased whole-body fatty 
acid oxidation in high-fat fed mice compared to chow fed mice.  
Skeletal muscle adapts to obesity and insulin resistance by altering the abundance of certain 
proteins. With a state-of-the-art mass spectrometry-based workflow, we identified over 6,000 
proteins in quadriceps muscle of lean and morbidly obese, insulin resistant mice lacking the 
satiety hormone leptin (ob/ob mice). Enzymes involved in lipid metabolism and proteins 
characteristic for slow oxidative type I muscle fibers were among the 118 differentially 
abundant proteins in skeletal muscle from obese in comparison to lean mice. Together with the 
increased abundance of proteins associated with mitochondria and peroxisomes, key organelles 
in the handling of energetic processes and cellular stress, this data indicates that obesity 
increases fatty acid oxidation in skeletal muscle. 
In conclusion, the enzymes DGKε and AMPK, with its regulatory subunits γ1 and γ3, 
modulate skeletal muscle energy homeostasis and influence whole-body glucose and lipid 
metabolism. We find that obesity and insulin resistance are associated with the remodeling of 
the proteome of skeletal muscle suggesting increased lipid oxidation. 
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Over the course of the last century, our life has changed towards a more sedentary lifestyle 
paired with a constant availability of calorie-dense food in most parts of the world. Elevator 
rides to the first floor, stationary computer work and the possibility to order pizza online at 2 
AM have made it unnecessary for many to use more energy than they consume throughout the 
day. The result is that in 2017, the WHO reported that nearly 2 billion adults in the world are 
overweight (body mass index (BMI) ≥ 25 kg/m2) and 650 million are obese (BMI ≥ 30 kg/m2) 
with a continuing upward trend causing this to be considered an “epidemic”, a term usually 
only associated with quickly spreading infectious diseases. In addition to obese adults, 41 
million children under the age of 5 are considered overweight or obese. Altogether this is an 
alarming development, given the impact of obesity-associated health impairments (WHO, 
2017b). Non-communicable diseases cause 70% of deaths worldwide, ranging from 38% in 
low income nations to 88% in wealthy nations. Cardiovascular diseases are currently leading 
the ranking of the deadliest diseases (WHO, 2017d). Weight gain and obesity are caused by a 
positive energy imbalance over a prolonged period of time, during which the onset of metabolic 
diseases often goes unnoticed. Nearly 90% of all 150 million cases of diabetes in the world can 
be accounted to type 2 diabetes mellitus (often referred to as T2D) and this number is expected 
to double by 2025 due to the rise of overweight and obesity (WHO, 2017a). A better 
understanding of molecular processes involved in the manifestation of metabolic diseases like 
T2D can help combat one of the major health threats of our time and advance the development 
of effective treatment strategies. 
1.1 TYPE 2 DIABETES AND GLUCOSE METABOLISM 
T2D is characterized by a disturbed maintenance of circulating blood glucose caused by 
insulin resistance in peripheral tissues in combination with a relative lack of insulin. Under 
euglycemic hyperinsulinemia, skeletal muscle glucose uptake accounts for up to 85% of total 
glucose uptake from the blood (DeFronzo et al., 1981). This makes skeletal muscle one of the 
major organs in the regulation of whole-body glucose homeostasis. Moreover, this explains 
why skeletal muscle insulin resistance has detrimental effects already early in the pathogenesis 
of T2D (Moller et al., 1996, Zierath et al., 1998, Ferrannini, 1998). 
1.1.1 Insulin action 
The rise in blood glucose in conjunction with a meal stimulates the pancreatic β-cells to 
produce and secrete the hormone insulin into the systemic circulation. Insulin binds to the 
insulin receptor (IR) on the plasma membrane of the responsive cells (House and Weidemann, 
1970, Ashcroft et al., 1972, Le Marchand-Brustel et al., 1978). The insulin receptor functions 
as a tyrosine kinase and autophosphorylates IR tyrosine residues upon ligand binding which 
then allows the interaction with the insulin receptor substrate 1 (IRS1) and its phosphorylation 
(Kasuga et al., 1982, Sun et al., 1991). This binding triggers the activation of the 
phosphoinositide (PI) 3-kinase pathway. The stimulation of the phosphoinositide-dependent 
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kinase 1 (PDK1) activates Akt which, as one of its actions, phosphorylates and hence 
inactivates its substrate AS160 (Akt substrate of 160 kDa, also TBC1D4) promoting the 
translocation of glucose transporter 4 (GLUT4) vesicles to the plasma membrane (Alessi et al., 
1997, Shepherd et al., 1997, Larance et al., 2005) (Fig. 1). Glucose transport is mediated by 
GLUT4 and glucose is phosphorylated by hexokinase (or glucokinase in the liver) resulting in 
the entrapment of the charged molecule glucose-6-phosphate in the cytoplasm. Glucose-6-
phosphate is now either entering glycolysis where it is converted into pyruvate and energy is 
released in the form of ATP or it is converted and stored as glycogen. The latter is also induced 
by the activation of Akt which furthermore stimulates protein synthesis via the mammalian 
target of rapamycin (mTOR) pathway, as well as cell survival by inhibiting autophagy (Withers 
et al., 1997, Sekulic et al., 2000).  
1.1.2 Glycogen and gluconeogenesis 
Since the cell has no ability to store ATP for later use, energy has to be stored in other forms. 
Following several enzymatic steps that metabolize glucose-6-phosphate into UDP-glucose, 
glycogen synthase (GS), together with the glycogen branching enzyme, build up glycogen, a 
cellular glucose storage molecule. The main organs storing glycogen are skeletal muscle and 
liver. Of these two organs, only the liver is able to break down glycogen to release glucose 
back into the blood during periods of fasting to maintain stable blood glucose levels. In 
addition, hepatic gluconeogenesis, the process of generating glucose from other sources than 
carbohydrates, is stimulated by the pancreatic peptide hormone glucagon and inhibited by 
insulin through the activation of Akt and the inhibition of the expression of the key 
gluconeogenic genes phoshphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (Liao et al., 1998, Kotani et al., 1999). Skeletal muscle breaks down glycogen 
when the energy demand within the muscle is high, for example during exercise. 
Figure 1: Insulin-stimulated glucose uptake. The binding of insulin to the insulin receptor (IR) triggers a 
signaling cascade through IRS1 and PI 3-kinase and results in the translocation of GLUT4 molecules to the plasma 
membrane allowing glucose to enter the cell. 
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1.2 SKELETAL MUSCLE, EXERCISE AND TYPE 2 DIABETES 
Exercise increases the uptake of glucose into skeletal muscle cells independently of insulin. 
This mechanism of action is preserved in insulin resistant skeletal muscle from severely 
diabetic rodents (Wallberg-Henriksson and Holloszy, 1984) and in turn even enhances insulin 
sensitivity (Wallberg-Henriksson et al., 1988). In humans, exercise training (7 days 1 hour/day 
of 75% maximal oxygen consumption) increases insulin-stimulated glucose uptake and PI 3-
kinase activity in skeletal muscle in comparison with the sedentary condition before training 
(Houmard et al., 1999). Skeletal muscle from obese type 2 diabetic subjects following a similar 
training protocol shows elevated GLUT4 abundance after training (O'Gorman et al., 2006). 
The gene expression profile of skeletal muscle is altered from hours up to several days post-
exercise or muscle contraction mediating long-term effects on whole body physiology 
(Mahoney et al., 2005, Neubauer et al., 2014). Additionally, exercise reduces the pancreatic 
secretion of insulin which is a desirable effect in stages of early insulin resistance where the 
pancreas increases the secretion of insulin to counteract the reduced effect on peripheral tissues 
(Jones et al., 1997, Rynders et al., 2014). This underlines the importance of regular exercise in 
the prevention of T2D in people with impaired glucose tolerance and insulin resistance and 
treatment of people with overt T2D. The WHO currently recommends 150 minutes of moderate 
intensity or 75 min of high intensity physical activity per week for adults (WHO, 2017c). This 
recommendation takes into account that short but intense training forms like HIIT (high-
intensity interval training) were shown to have similar effects on skeletal muscle physiology 
and overall health as longer but moderate workouts (Perry et al., 2008, Shaban et al., 2014). 
1.2.1 Skeletal muscle fiber types 
Skeletal muscle is composed of multinucleated muscle fibers consisting of several 
myofibrils. Myofibrils are subdivided into sarcomers which are repeated units of actin and 
myosin filaments that form the functional machinery required for muscle contraction. Upon 
stimulation of the neuro-muscular junction via the central nervous system, the muscle fiber 
depolarizes through the opening of sodium channels and calcium is released by the 
sarcoplasmic reticulum. Calcium binds to the protein troponin which undergoes 
conformational changes exposing the myosin binding site on the actin filament (Ebashi et al., 
1967). The myosin filaments can now pull the actin filament closer in an ATP-hydrolyzing step 
resulting in a shortened muscle (Huxley and Niedergerke, 1954).  
Skeletal muscle fibers are divided into several fiber types which are primarily characterized 
by the presence of different myosin heavy chain isoforms that define the contractile properties, 
fuel use and fatigability of a fiber. The main isoform in slow-twitch type I fibers with a high 
oxidative capacity and low but steady power output is the myosin heavy chain β that is encoded 
by MYH7. The moderately fast type IIa fibers that have high oxidative and glycolytic capacities 
express the isoform MYH2, while MYH1 expression is characteristic for fast type IIx fibers 
(also referred to as IId) that are used for short-term anaerobic activity. Type IIb fibers are the 
fastest fibers used for very short and explosive bouts of activity. They are exclusively glycolytic 
and characterized by the expression of the myosin heavy chain isoform MYH4 (Larsson et al., 
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1991, DeNardi et al., 1993, Schiaffino and Reggiani, 2011). While the extent to which muscle 
fibers can interconvert remains a matter of debate, endurance training in humans leads to 
changes in the relative distribution of oxidative type I fibers, while strength training has an 
effect on the relative type II fiber distribution (Wilson et al., 2012).  
Some variation in muscle fiber types exists between mammalian species. Small rodents 
generally have a higher proportion of fast-twitch fibers in each muscle compared to humans 
(Schiaffino and Reggiani, 2011). In rat skeletal muscle, several hybrid fibers were described, 
suggesting a continuity with these hybrids as intermediates between the different pure muscle 
fibers (Rivero et al., 1998). In C57BL/6J wildtype mice, the hindlimb muscle soleus was shown 
to contain a high proportion of oxidative slow-twitch fibers, while the extensor digitorum 
longus (EDL) muscle consists of glycolytic fibers. Tibialis anterior (TA), quadriceps and 
gastrocnemius are mixed muscles with mainly glycolytic, but also oxidative fibers (Bloemberg 
and Quadrilatero, 2012, Jacobs et al., 2013). The oxidative capacity is reduced in vastus 
lateralis muscle of T2D patients, with reduced slow oxidative and increased glycolytic fibers 
compared with healthy controls (Oberbach et al., 2006). However, the cause and consequence, 
as well as the underlying molecular mechanisms of these changes is unclear, especially 
regarding the abundance and functionality of skeletal muscle mitochondria in obesity or insulin 
resistant states. 
1.3 LIPID METABOLISM 
The complete oxidation of lipids, compared to carbohydrates and protein, the other two 
macronutrient classes, yields the most ATP per gram. Fat is mainly stored in the form of 
triglycerides, with three chains of saturated or unsaturated fatty acids bound to one molecule 
of glycerol as a backbone. In order to utilize this stored fat, triglycerides have to undergo 
lipolysis where the glycerol bond is digested by lipases and free fatty acids are released. This 
is, for example, stimulated by glucagon triggering adipocytes to secrete free fatty acids into the 
blood when glucose levels are low and energy is needed. Fatty acids are transported into 
mitochondria as acyl-CoA by carnitine palmitoyltransferase 1 (CPT1) where they undergo ß-
oxidation (McGarry et al., 1978). β-oxidation produces an acyl-CoA molecule that is two 
carbon atoms shorter than before, an acetyl-CoA molecule that can now enter the tricarboxylic 
acid (TCA) cycle, and NADH as well as FADH2. If acetyl-CoA does not enter the TCA cycle, 
it can be carboxylated by the acetyl-CoA carboxylase (ACC) into malonyl-CoA. Malonyl-
CoA, in turn, is the substrate for fatty acid synthesis and inhibits the further transport of fatty 
acids into the mitochondria (Ruderman and Dean, 1998, Rasmussen et al., 2002). 
Although lipid metabolism and the plasma concentrations of fatty acids are not as tightly 
regulated as the metabolism of glucose, there is a sensitive regulatory network in place 
involving many enzymes and inter-organ crosstalk. With metabolic dysregulation and obesity, 
lipids accumulate within skeletal muscle and liver which can be directly linked to insulin 
resistance (Kelley and Goodpaster, 2001). Diacylglycerols (DAGs) and other fatty acid 
metabolites activate kinases like protein kinase C (PKC), the inhibitor of nuclear factor κB 
kinase-B (IKKB) and the c-Jun N-terminal kinase (JNK) that phosphorylate IRS and reduce 
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insulin signal transduction (Samuel et al., 2004). Paradoxically, elevated levels of triglycerides 
can also be detected in skeletal muscle of endurance trained athletes with a high oxidative 
capacity (Goodpaster et al., 2001). 
1.3.1 Adipose tissue 
Adipocytes form one of the most dynamic tissues in the body, with the ability to expand 15-
fold in size (Berry et al., 2013). With the main purpose of storing fat in times of overabundance 
of nutrients, adipose tissue also plays an important role in thermoregulation and the 
coordination of systemic metabolism. Over the last three decades, adipose tissue has been 
recognized as the largest endocrine organ taking part in the regulation of food intake, glucose 
homeostasis and fertility through the secretion of hormones, lipids and adipokines (Zhang et 
al., 1994, Hotamisligil et al., 1995, Hu et al., 1996, Mathew et al., 2017). Histologically, there 
are two main classes of adipose tissue in the body: White adipose tissue (WAT) which can be 
subdivided into visceral and subcutaneous depots and brown adipose tissue (BAT). In contrast 
to WAT, BAT is very rich in mitochondria and dissipates energy and produces heat through 
the uncoupling of the electron transport chain. The key characteristic of brown adipocytes is 
the expression of the uncoupling protein 1 (UCP1) (Nicholls et al., 1978, Lin and Klingenberg, 
1980). BAT plays an important role in thermoregulation during the neonatal period, but 
expansion and activity of the main depot between the scapulae can also be induced in most 
adults through cold exposure (Cypess et al., 2009, van Marken Lichtenbelt et al., 2009, 
Yoneshiro et al., 2011). Due to its fat burning capacity, the induction of BAT and the 
“browning” of so called “beige” or “brite” adipocytes that constitute an intermediate adipocyte 
type within certain white fat depots have been investigated thoroughly during the last years 
providing a base for possible therapeutic approaches (Petrovic et al., 2010, Ohno et al., 2012, 
Kalinovich et al., 2017).  
The location of the different white adipose tissue depots defines their response to stimuli, as 
well as their impact on the regulation of whole-body energy metabolism through distinct 
patterns of gene expression (Alves et al., 2017). The accumulation of subcutaneous fat 
(referring to the “pear-shaped” female fat distribution) is believed to be healthier than the 
accumulation of visceral intra-abdominal fat (as in the male “apple-shaped” fat distribution). 
Regarding the estimation of metabolic health, an evaluation of the waist-to-hip ratio rather than 
the BMI is (with a waist-to-hip ratio > 0.85 for women and > 0.9 for men being considered a 
greater metabolic risk according to the WHO (WHO, 2008)) is recommended. Thus, alterations 
in not only the amount, but also the distribution of fat impact metabolic health. Moreover, in 
mice, transplantation of subcutaneous adipose tissue into locations of visceral depots improves 
metabolic parameters (Tran et al., 2008). Recently, WAT has been recognized as a direct 
exercise-responsive tissue and the secretion of transforming growth factor (TGF) β2 from 
subcutaneous adipose tissue of endurance trained mice has been identified as a factor 
promoting exercise-related health benefits. The transplantation of subcutaneous WAT from 
trained into untrained mice improved metabolic parameters in the sedentary recipients leading 
to the discovery of this adipokine (Stanford et al., 2015). Overall, the role of adipose tissue as 
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an endocrine organ is not fully understood, and further studies in the context of metabolic 
homeostasis and exercise-responsiveness are warranted. 
1.3.2 Leptin action 
The satiety hormone leptin is secreted by the white adipose tissue during and after a meal, 
as well as during sleep. Leptin is involved in the central regulation of food intake and 
neuroendocrine function. Within the arcuate nucleus, located in the ventromedial 
hypothalamus just above the optic chiasm, leptin-sensitive agouti-related peptide (AgRP) and 
pro-opiomelanocortin (POMC) neurons integrate this signal and inhibit further food intake 
(Cheung et al., 1997, Ebihara et al., 1999, Coppari and Bjorbaek, 2012). Leptin was first 
discovered in the mid-1990s after the successful positional cloning of the obese gene that 
causes extreme heritable obesity in the ob/ob mouse strain already described in 1950 by the 
Jackson Laboratory (Zhang et al., 1994, Ingalls et al., 1950). When the structure of the hormone 
and the effect of leptin was revealed, high hopes were put into the “wonder drug against 
obesity”. However, obesity is in most cases accompanied by leptin resistance, rather than leptin 
deficiency, and therefore the additional administration of leptin has little or no slimming effect 
(Frederich et al., 1995, Ronnemaa et al., 1997, Westerterp-Plantenga et al., 2001, Steinberg et 
al., 2002). Rare cases of extremely obese humans with a mutation causing the complete absence 
of leptin expression in adipose tissue benefit from leptin treatment to reduce weight and other 
neuroendocrine pathologies (Farooqi et al., 1999). In addition to the direct effect on feeding 
behavior, leptin exerts multiple effects on glucose homeostasis via central and peripheral 
mechanisms. The infusion of leptin into the cerebral ventricles reduces hepatic 
gluconeogenesis and increases peripheral glucose uptake (Kamohara et al., 1997, Liu et al., 
1998). In vitro studies provide evidence for a direct effect of leptin treatment on glucose 
metabolism in isolated skeletal muscle cells (Harris, 1998, Bates et al., 2002). The ob/ob mouse 
line continues to be a widely used model for extreme hyperphagic obesity, insulin resistance 
and transient hyperglycemia on a C57BL/6J genetic background (Lindstrom, 2007). 
1.4 MITOCHONDRIA AND PEROXISOMES 
Mitochondria are essential for cellular metabolic homeostasis as they harbor the enzymes 
constituting the TCA cycle needed for the generation of ATP from glucose, lipids or proteins. 
Different tissues have different amounts of mitochondria with oxidative skeletal muscle, such 
as soleus muscle, cardiac muscle or BAT being rich in mitochondria. Besides the production 
of ATP, mitochondria are involved in the generation of reactive oxygen species (ROS), calcium 
signaling and the regulation of cell death. Mitochondrial biogenesis is stimulated through 
environmental stress such as exercise and the activation of the peroxisome proliferator-
activated receptor gamma coactivator 1-α (PGC-1α) that contributes to the regulation of the 
expression of specific genes. Mitochondrial DNA is a circular molecule similar to bacterial 
DNA and contains 37 genes that encode 13 subunits of the electron transport chain complexes. 
However, the large majority of mitochondrial proteins are encoded in the nuclear DNA 
(Jornayvaz and Shulman, 2010). The most prominent member of the sirtuin family, SIRT1, has 
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also been linked to mitochondrial biogenesis via the deacetylation and hence stimulation of 
PGC-1α. This was proposed to be the mechanism behind the impact SIRT1 has on the 
metabolic adaptations observed during caloric restriction and longevity (Gerhart-Hines et al., 
2007, Tang, 2016). 
The electron transport chain located in the inner mitochondrial membrane consists of five 
complexes that together constitute the oxidative phosphorylation (OxPhos) system. The 
oxidation of NADH and FADH2 from the TCA cycle to NAD
+ and FAD generates free 
electrons that flow through the complexes and build up a proton gradient across the membrane. 
The complete chain of redox reactions results in the production of water and the proton gradient 
drives the ATP synthase resulting in the formation of ATP from ADP and phosphate. 
1.5 AMP-ACTIVATED PROTEIN KINASE 
The AMP-activated protein kinase (AMPK) can be considered the main energy sensor in 
the cell. The enzyme is activated through elevated levels of AMP (or ADP) arising from the 
utilization of ATP in periods of high energy demand (Ross et al., 2016). AMP binds to the γ-
subunit of the heterotrimeric complex and promotes an allosteric modulation involving an 
activating phosphorylation (Thr172) of the α-subunit and exposure of its catalytic site (Fig. 2, 
(Steinberg and Kemp, 2009)). Upon activation, AMPK phosphorylates a plethora of target 
enzymes inducing glucose uptake, glycolysis and lipid oxidation to generate ATP while 
inhibiting energy storing processes such as glycogenesis and triglyceride formation (Fig. 3). 
The three different subunits comprising AMPK exist in different isoforms and are encoded by 
different genes: The catalytic subunit (α1 and α2), the scaffolding subunit (β1 and β2) that also 
plays a glycogen-sensing role and the regulatory AMP-sensing subunit (γ1, γ2 and γ3) 
(Stapleton et al., 1996, Cheung et al., 2000, Polekhina et al., 2003). The enzyme is only 
functional as a triad and can exist in 12 different heterotrimeric combinations that are expressed 
in a tissue-specific manner and possibly exhibit different levels of activity depending on the 
stimulus (Mahlapuu et al., 2004, Willows et al., 2017). Together this allows a fine tuned 
regulation of metabolic homeostasis in peripheral and central tissues via AMPK.  
1.5.1 AMPK in glucose and lipid metabolism 
The acute activation of AMPK, for example during exercise, when skeletal muscle has an 
increased energy demand, promotes the translocation of the glucose transporter GLUT4 to the 
plasma membrane, allowing an increased influx of glucose into the cell (Kurth-Kraczek et al., 
1999). Since AMPK simultaneously phosphorylates serine residues on the enzyme GS, the 
channeling of glucose into the production of glycogen is inhibited and ATP-producing 
glycolysis is favored instead (Wojtaszewski et al., 2002). However, the chronic activation of 
AMPK, for instance caused by activating mutations within the subunit genes, results in the 
accumulation of glycogen in the cell, as the permanently high levels of glucose-6-phosphate 
allosterically activate the GS presumably overwriting the direct inhibition through AMPK 
(Nielsen et al., 2002, Barnes et al., 2005).  
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While glycogen stores in skeletal muscle are needed for bursts of intense exercise, skeletal 
muscle mainly relies on fatty acids as fuel source during prolonged endurance exercise or when 
at rest (van Hall et al., 2002). AMPK is involved in the induction of lipid oxidation via the 
inhibition of ACC. ACCα/β promotes lipid synthesis rather than oxidation, and its inhibition 
by the AMPK-induced phosphorylation of the critical residue Ser79 decreases the levels of 
malonyl-CoA, which in turn results in reduced inhibition of CPT1, the transporter of long chain 
fatty acids in the mitochondria. The import of lipids into the mitochondria is now increased, 
elevating the β-oxidation rate (Kudo et al., 1995). AMPK furthermore exerts long-term 
transcriptional control of metabolic key enzymes (Long et al., 2005). 
1.5.2 Mutations modulating AMPK activity 
Commonly prescribed anti-diabetes drugs like metformin have been shown to activate 
AMPK (Zhou et al., 2001). Moreover, specific AMP-analogs like 5-aminoimadazole-4-
carboximide-1-β-4-ribofuranoside (AICAR) are available. However, AMPK activity is also 
directly and chronically activated by mutations that affect the protein structure of the regulatory 
or catalytic residues (Merrill et al., 1997, Musi et al., 2002, Viollet and Foretz, 2016). Several 
of these mutations occur naturally, while others have been introduced artificially into animal 
models to study the function of AMPK in the regulation of tissue-specific, as well as whole-
body energy metabolism. In humans, an activating mutation within the gene of the heart-
specific γ2 isoform has been linked to the hereditary Wolff-Parkinson-White syndrome, which 
is associated with increased cardiac glycogen storage and tachycardia (Gollob et al., 2001). 
However, the best described AMPK mutation occurs naturally in Hampshire pigs and causes a 
vast accumulation of glycogen in skeletal muscle, as well as elevated levels of citrate synthase 
activity associated with an increased oxidative capacity (Milan et al., 2000, Granlund et al., 
2010). This gain-of-function point mutation (AMPKγ3R225Q) mainly affects glycolytic skeletal 
muscle, as the γ3-subunit is primarily expressed in glycolytic fibers (Mahlapuu et al., 2004). 
When this mutation was introduced into mice, it was furthermore shown that it protects against 
Figure 2: Graphical representation of 
the mammalian heterotrimeric AMPK 
complex and the yeast orthologs: In blue, 
the α-subunit with a mammalian β-subunit 
interacting domain (SID) and regulatory 
sequence possibly unique to S. cerevisiae 
(RS). In green, the β-subunit structure with 
a carbohydrate-binding molecule (CBM) 
(from S. cerevisiae) and αγ-subunit binding 
sequence (SBS) (from S. pombe). In red, 
the mammalian γ-subunit structure with 
three AMP molecules (yellow) and one 
ADP molecule (orange) bound in the 
center formed by CBS domains. From 
Steinberg and Kemp, 2009. 
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intramuscular triglyceride accumulation and stimulates mitochondrial biogenesis. Moreover, 
this mutation protects against diet-induced insulin resistance, underlining not only the impact 
of tissue-specific AMPK activity on bioenergetics, but also the important role skeletal muscle 
plays in the regulation of whole-body metabolism in general (Barnes et al., 2004).  
A similar mutation, also causing elevated glycogen levels and reduced intramuscular lipids, 
was described in the highly conserved human PRKAG3 gene (AMPKγ3R225W) (Costford et al., 
2007). Gain-of-function mutations of the γ-subunit often render the complex constitutively 
active, as the altered protein structure bypasses the need for AMP to activate the enzyme 
complex. Although the role of AMPKγ3 has been studied extensively in the context of 
glycolytic skeletal muscle, the impact of alterations of AMPK activity in skeletal muscle via 
the mutation of the γ-subunit on whole-body glucose and lipid metabolism is not well 
understood. Additionally, the role the other γ-isoforms, especially AMPKγ1, play in metabolic 
regulation remains unclear. AMPKγ1 appears to be the most common γ-subunit in AMPK 
complexes in skeletal muscle, even though it is not as highly expressed as γ3 (Mahlapuu et al., 
2004, Wojtaszewski et al., 2005). 
The regulatory network of AMPK is very complex and in addition to gain-of-function 
mutations of the enzyme, loss of one or several subunit isoforms can have metabolic effects. 
In skeletal muscle, the AMPKγ isoforms appear to functionally compensate, to some extent, 
for the loss of one another. Moreover, AMPKγ3 knockout (KO) mice only show mild 
impairments in glycogen storage and glycogen resynthesis in EDL muscle, with preserved 
exercise capacity (Barnes et al., 2004). In contrast, the global deletion of both α-isoforms is 
embryonically lethal (Viollet et al., 2009). While the deletion of only AMPKα1 results in 
reduced lean mass and adiposity of mice (Daval et al., 2005, Fu et al., 2013), the deletion of 
AMPKα2 causes a diabetic phenotype, with insulin resistance and impaired glucose tolerance 
(Viollet et al., 2003). This sheds light on the interaction of AMPKα1 and α2, which are both 
expressed in tissues regulating glucose homeostasis such as liver and skeletal muscle.  
Only in recent years, the role of the β-subunit of AMPK has been investigated more 
thoroughly since this subunit was previously believed to only fulfill a scaffolding function 
within the complex. Interestingly, AMPKβ1 KO mice show a lean phenotype, with a 90% 
reduction of AMPK activity in liver and no change in skeletal muscle or heart (Dzamko et al., 
2010). Conversely, AMPKβ2 KO mice show reduced AMPK activity in skeletal muscle, with 
impaired exercise capacity and increased susceptibility to diet-induced obesity (Steinberg et 




Figure 3: Regulation of metabolism by AMPK. Various stimuli activate AMPK and induce 
catabolic signals to generate more ATP, while inhibiting anabolic energy-storing pathways. 
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1.6 DIACYLGLYCEROL KINASES 
Diacylglycerol kinases (DGKs) are a family of enzymes that drive the conversion of 
diacylglycerol (DAG) to phosphatidic acid (PA). Both lipids have distinct signaling, as well as 
metabolic functions. Thus, DGKs provide a link between lipid metabolism and signaling (Fig. 
4). Ten different DGK isoforms, in addition to some alternatively spliced variants, have been 
described in mammals (α, β, γ, δ, ε, ζ, η, θ, ι and κ). DGKs are stimulated upon PI 3-kinase 
pathway activation, as well as by other upstream regulators such as Src kinase or PKC, in an 
isoform-specific manner (Sakane et al., 2007). All isoforms have at least two common cysteine-
rich C1 domains that are associated with DAG binding and a catalytic domain (Imai et al., 
2005, Shulga et al., 2011). Based on other structural motifs and homology domains, these ten 
isoforms can be further divided into five subtypes, which possibly carry out distinct biological 
functions. Several different DGK isoforms can be found to be co-expressed in most cells and 
tissues (Crotty et al., 2006), with tissue-specific expression profiles for example in skeletal 
muscle, where DGKα and ζ have been found to be most abundantly expressed in EDL and 
DGKδ in soleus muscle of mice (Manneras-Holm et al., 2015). 
Besides the tissue-specificity of DGK isoforms, the functionality has been investigated in 
regard to the subcellular localization. Several isoforms were found to shuttle in and out the 
nucleus, while others are stimulus-dependent or permanently associated with the plasma 
membrane (Kobayashi et al., 2007). PA, the product of the DAG conversion that is catalyzed 
by DGK, is involved in the regulation of cellular events such as proliferation, cell survival, 
vesicle trafficking, as well as the phosphatidylinositol (PI) cycle involving lipid movement 
between cell organelles (Cazzolli et al., 2006). DGKε appears to be the only isoform that shows 
substrate specificity for DAG with arachidonoyl acyl chains in the sn-2 position and is thus 
directly involved in the PI cycle, as all intermediates of this cycle are rich in arachidonoyl 
groups (Tang et al., 1996). Studies in knockout mouse models have established that DGKε is 
involved in the regulation of seizure susceptibility and that DGKα and ζ play important roles 
in the regulation of the function of lymphocytes linking DGKs to cancer (Olenchock et al., 
2006, Rodriguez de Turco et al., 2001). All DGK isoforms are found in the central nervous 
system and directly associated with neuronal and glial function (Goto and Kondo, 2004).  
Figure 4: Role of diacylglycerol kinase in lipid signaling and metabolism. DGK 
drives the phosphorylation of the free hydroxyl group of DAG to produce phosphatidic 
acid. 
 12 
1.6.1 Role of DGKs in metabolism 
In metabolically active tissues, DAG levels and DGK activity have been directly linked to 
metabolic health as insulin resistance is associated with increased intracellular DAG levels 
(Kraegen et al., 2006). A reduced expression of DGKδ was found in skeletal muscle from type 
2 diabetic subjects and DGKδ haploinsufficiency in mice has been shown to be sufficient to 
reduce peripheral insulin sensitivity and promote age-dependent obesity (Chibalin et al., 2008). 
Low-intensity exercise in type 2 diabetic patients improves clinical parameters such as HOMA-
IR, a measurement of insulin resistance, and also increases DGKδ expression in skeletal 
muscle, underlining the tie of DGKs to metabolic homeostasis (Fritz et al., 2006). Diminishing 
expression levels of DGKα and DGKγ in pancreatic β-cells attenuates the secretion of insulin 
while the global loss of DGKζ protects against diet-induced peripheral insulin resistance 
(Kurohane Kaneko et al., 2013, Benziane et al., 2017). In addition, the abundance of DGKε 
mRNA was found to be reduced in EDL muscle and epididymal adipose tissue from obese 
insulin resistant ob/ob mice (Manneras-Holm et al., 2015). However, the role of DGKε, with 
its distinct biological function regarding the conversion of certain lipid species, in the 




The importance of the regulation of whole-body energy homeostasis by skeletal muscle is 
eminent in light of the detrimental effects of skeletal muscle insulin resistance and reduced 
metabolic flexibility on the whole organism. The roles of two kinases constituting regulatory 
hubs in this system, DGKε and AMPK, and their effect on glucose and lipid metabolism in 
skeletal muscle and the whole body are incompletely understood. Characterizing the function 
of these enzymes in the regulation of metabolism may aid the understanding of causative 
mechanisms and potential prevention strategies for the treatment of metabolic diseases. In 
addition, gaining insights into the plethora of cellular changes in skeletal muscle concomitant 
with the increased exposure to glucose and fatty acids in obesity could help identify novel 
treatment targets for insulin resistance. 
The aims of this thesis are therefore to: 
 Elucidate the contribution of DGKε to the regulation of energy homeostasis on the 
whole-body level and in skeletal muscle in relation to insulin resistance and obesity. 
 
 Characterize the role of the regulatory skeletal muscle AMPK subunits γ1 and γ3 in 
the maintenance and regulation of whole-body glucose and lipid metabolism and the 
effects skeletal muscle AMPK activation has on other peripheral tissues. 
 
 Identify changes in the skeletal muscle proteome of leptin-deficient and insulin 
resistant ob/ob mice to further characterize metabolic adaptations to obesity that 
could be targeted with pharmacological approaches. 
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3 EXPERIMENTAL CONSIDERATIONS 
This section focuses on specialized in vivo and in vitro methods that are not routinely used 
in general biomedical laboratories (such as immunoblotting or quantitative PCR) but that were 
used in the animal studies presented in this thesis.  
3.1 ANIMALS 
All mice used in the studies presented were bred on a C57BL/6J background and, unless 
indicated otherwise, had free access to standard rodent chow and water and were housed in 
group cages in a temperature controlled environment (24ºC) with a 12 hours light/dark cycle. 
All experiments were approved by the regional animal ethical committee, Stockholm, Sweden. 
The models used in paper I-IV are presented in Table 1 and the generation of the model used 
in paper II is described in more detail below. 
Table 1 
Study Animal model Details 
Paper I DGKε knockout 
Whole-body deletion of exon 1 of DGKε 
(Rodriguez de Turco et al., 2001), the only 
diacylglycerol kinase with a hydrophobic segment 
(Decaffmeyer et al., 2008). 
Paper II AMPKγ1H151R 
MLC1-Cre-induced expression of an activating 
AMPKγ1H151R transgene specifically in skeletal 
muscle. 
Paper III AMPKγ3R225Q 
Skeletal muscle-specific MLC1-promoter driven 
expression of an activating AMPKγ3R225Q 
transgene (Barnes et al., 2004). 
Paper IV ob/ob 
Complete lack of leptin due to a mutation in the 
obese gene (Ingalls et al., 1950). 
To generate the skeletal muscle-specific AMPKγ1H151R mouse line, mice expressing Cre 
recombinase under the myosin light chain (MLC1) promotor (kindly provided by Steven 
Burden, New York University Medical Center, NY, USA) were mated with mice carrying the 
Cre-inducible transgene AMPKγ1H151R. The transgene is under the control of the β-actin 
promotor and contains the mutated human PRKAG1 gene sequence located downstream of a 
stop sequence that is flanked by two loxP sites. This allows the specific expression of the 
transgene in skeletal muscle tissue due to the Cre-mediated excision of the stop sequence. 
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Histidine 151 in the human protein sequence refers to the previously described murine 
activating mutation of H150 in the CBS2 domain of the AMP-binding site of AMPKγ1 
(Minokoshi et al., 2004). In paper II, we studied female and male floxed (fl/fl) AMPKγ1H151R 
MLC1-Cre mice and wildtype littermates bred on mixed C57BL/6J background. 
3.2 IN VIVO TECHNIQUES 
3.2.1 Body composition 
EchoMRI-100 (EchoMRI LLC, Houston, TX, USA) scanning allows for the rapid 
assessment of body composition of conscious animals based on nuclear magnetic resonance 
(NMR) and gives measures of total body fat, lean mass, free water and total body water.  
3.2.2 Glucose tolerance 
For all glucose tolerance tests presented in this thesis, mice were fasted for 4 hours in single 
cages and thereafter 2 g/kg glucose was administered intraperitoneally. Blood glucose was 
measured in tail tip blood at 0, 15, 30, 60 and 120 min (OneTouch Ultra 2 glucose meter, 
Lifescan, Milpitas, CA, USA) following the injection. Serum insulin concentration was 
measured at 0 and 15 min using an ELISA with mouse insulin as a standard (Crystal Chem., 
Chicago, IL, USA). This in vivo procedure allows for the assessment of glucose clearance 
capacity from the blood and can give an indication of general insulin sensitivity. 
3.2.3 Hyperinsulinemic-euglycemic clamp 
Glucose clamp techniques are the gold standard for measuring glucose utilization and 
insulin sensitivity in vivo (DeFronzo et al., 1979) and we employed the hyperinsulinemic-
euglycemic clamp technique in conscious mice (Ayala et al., 2011). The assessment of 
peripheral insulin sensitivity is based on the quantification of glucose tracer clearance from the 
blood representing the general glucose turnover in combination with the quantification of the 
administered glucose required to maintain constant glycemia after insulin-mediated inhibition 
of hepatic glucose production and stimulation of peripheral glucose uptake.  
In paper II, jugular vein catheterization was performed on mice under isoflurane anesthesia 
with carprofen analgesic treatment on the day of surgery and one day after. Animals were left 
to recover and monitored for at least 4 days in single cages. Using a constant jugular vein 
infusion of [3-3H] glucose (2.5 µCi bolus and a flow rate of 0.04 µCi/min), glucose turnover 
rate was measured in the basal state and under hyperinsulinemic-euglycemic clamp conditions 
in 4-hour-fasted mice. Basal glucose utilization and hepatic glucose production was assessed 
50-70 min after the start of the tracer infusion right before the insulin infusion was started. The 
clamp was started with a priming dose of insulin (17.5 mU/kg; Actrapid, Novo Nordisk, 
Bagsvaerd, Denmark) followed by a constant infusion of insulin at a rate of 1.75 mU/kg/min. 
At steady state (~85 min after the start of the insulin infusion), blood samples were collected 
and whole-body glucose utilization was measured. Hepatic glucose production was calculated 
by subtracting the glucose infusion rate from the glucose utilization. Additional blood samples 
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were taken at basal and clamped state to determine serum insulin concentrations by ELISA. 
Animals were euthanized with an overdose of sodium pentobarbital. 
3.2.4 Whole-body energy homeostasis (metabolic cages) 
Housing animals in metabolic cages allows for the simultaneous measurement of food 
intake, water consumption, movement, heat production, O2 consumption (VO2), CO2 
production (VCO2), and the calculation of the respiratory exchange ratio (RER) over hours or 
days. This analysis gives insight into whole-body metabolism and changes caused by mutations 
or dietary interventions. The RER indicates whether carbohydrates or lipids are primarily 
metabolized, with an RER close to 1 indicating carbohydrate utilization and values close to 0.7 
indicating lipid oxidation. In paper I and II, mice were acclimated for at least 24 hours in single 
cages and subsequently monitored for up to 2 days in the Oxymax Lab Animal Monitoring 
System (CLAMS, Columbus Instruments, Columbus, OH, USA) with ad libitum access to food 
and one night without access to food (12-hour fasting, only in paper II). In this system, the gas 
exchange was recorded every 20 min by sampling the air from the individual cages and passing 
it through sensors to determine the O2 and CO2 content. Spontaneous locomotor (ambulatory) 
activity was measured by consecutive light beam breaks of adjacent beams on the X, Y and Z 
axes. An alternative metabolic cages system for small rodents is the TSE PhenoMaster home 
cage system (TSE Systems, Germany) that also allows for the adjustment of the light/dark cycle 
and the temperature as the cages are inside cabinets to control the environment beyond the gas 
exchange.  
3.2.5 Fatty acid oxidation 
To assess the whole-body fatty acid oxidation rate in conscious mice as described in paper 
III, chow and high-fat diet fed male AMPKγ3R225Q and wildtype littermates were catheterized 
as described for the hyperinsulinemic-euglycemic clamp above. Prior to the experiment, mice 
were fasted for 2 hours and body weight was recorded, glycemia measured and fasted blood 
samples were collected. Blood samples were subjected to centrifugation for 6 min at 10,000g 
(4°C) and plasma stored at -80°C. Infusate per mouse was prepared with 107 DPM of [9,10-
3H(N)]-Palmitic Acid (NET043001MC, PerkinElmer, CA, USA) and 107 DPM of non-
oxidizable [1-14C]-2-bromopalmitic acid (MC 451, Moravek Inc., CA, USA) dried under a 
nitrogen steam and reconstituted in 100 µl of saline containing 1.2% BSA and 0.15 mM 
palmitate. Before the start of the infusion of the tracer (t=0), the catheter was flushed with saline 
to ensure patency and the infusion rate set to 20 μl/min. Blood samples (15 µl) were collected 
from the cut tail tip using heparinized capillaries at t=0, 1, 3, 5, 7, 9 and 12 min and directly 
frozen in liquid N2. At t=5 min, the pump (Univentor, Malta) was disconnected and the catheter 
was flushed again with saline. After the last blood sample collection, mice were euthanized via 
an injection of pentobarbital sodium into the jugular vein (t=16 min) and skeletal muscle (TA, 
EDL and soleus), perigonadal white adipose tissue, liver and heart were dissected, cleaned from 
blood and quickly frozen in liquid N2. This time point was selected to ensure that the last blood 
sample collection could be finished for all animals and still ensure the same euthanasia time 
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point allowing the comparison of the analyzed tissues and the metabolites therein. In the case 
of pre-treatment, mice were injected with 5 mg/kg (+)-etomoxir sodium salt hydrate (Sigma 
Aldrich, Germany), an inhibitor of CPT1, dissolved in saline into the jugular vein 15 min prior 
to the tracer infusion. 
3.3 IN VITRO TECHNIQUES 
3.3.1 Glucose transport in isolated skeletal muscle 
In paper I, glucose uptake was assessed in vitro in isolated skeletal muscle from 4-hour-
fasted DGKε KO and wildtype mice. Mice were anaesthetized (2.5% Avertin; 0.02 ml/gram 
body weight) and EDL and soleus muscles were removed with intact tendons. Incubation media 
was prepared from a stock solution of Krebs-Henseleit bicarbonate buffer (KHB) 
supplemented with 5 mM HEPES and 0.1% bovine serum albumin (RIA grade) and 
continuously gassed with 95% O2/5% CO2 to maintain the muscles in a physiological 
environment. Following the dissection, muscles were incubated to recover at 30°C for 30 min 
in KHB containing 5 mM glucose and 15 mM mannitol. Muscles were then incubated for 30 
min in KHB with the same supplements as the recovery buffer but in the additional absence or 
presence of a submaximal dose of insulin (0.36 nM) and subsequently rinsed for 10 min in 
KHB containing 20 mM mannitol as well as insulin as before, but without glucose. Thereafter, 
muscles were incubated for 20 min in the absence or presence of insulin in KHB buffer 
containing 19 mM [14C] mannitol (0.7 mCi/ml) and 1 mM (3H) 2-deoxyglucose (2.5 mCi/ml), 
allowing for the quantification of insulin-stimulated glucose uptake by assessing the 
intracellular accumulation of [3H] 2-deoxyglucose-6-phosphate in the muscles (Wallberg-
Henriksson, 1987, Hansen et al., 1994).  
3.3.2 Lipid extraction of radioactive palmitate 
Several solvent-based systems are commonly used to extracts lipids from biological samples 
but especially the hexane-isopropanol system (Hara and Radin, 1978) was found to be suitable 
for extracting hydrophobic lipids, such as free fatty acids, triglycerides and cholesterol esters 
(Reis et al., 2013). In the blood and tissues samples collected during the in vivo fatty acid 
oxidation experiments described in paper III, the infused radioactive lipids were separated from 
the ß-oxidation by-product 3H2O (in the aqueous phase) as described (Massart et al., 2014). 
Samples were rotated overnight at room temperature with an addition of 300 µl 
isopropanol/0.1% acetic acid allowing the diffusion of the lipids into the solvent. Samples were 
then rotated for an additional 10 min after an addition of 600 µl hexane and 150 µl 1 M KCl 
which improves the removal of non-lipid contaminants (Hara and Radin, 1978). The phases 
were allowed to separate and the upper organic phase containing the lipids was collected, 
vacuum-dried for 1 hour and reconstituted in 50 µl methanol:chloroform (1:1) before being 
transferred into scintillation vials. The lower phase (aqueous phase) was treated with 300 µl 1 
M NaOH and shaken for 30 min at 50°C to dissolve cell debris. After neutralization with 300 
µl 1 M HCl, the samples were transferred into scintillation vials and radioactivity was measured 
(1414 Win Spectral Liquid Scintillation Counter, Wallac/PerkinElmer, Turku, Finland).  
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3.3.3 Proteomics of skeletal muscle tissue 
The identification of proteins and peptides with proteomics techniques is critically 
dependent on the sample preparation. As described in paper IV, the protein lysates from 
quadriceps muscle of male ob/ob mice and mouse myoblast C2C12 cells were processed with 
a multiple enzymes digestion with filter-aided sample preparation (MED-FASP) using the 
endoproteinase LysC and trypsin. LysC supplements the trypsin-mediated proteolysis, 
especially of tightly folded proteins, ensuring full protein cleavage (Swaney et al., 2010). The 
peptides were purified using C18 Stage tips that employ the principle of solid phase extraction 
with the analyte passing through a Teflon mesh with reversed-phase C18-coated silica beads 
binding non-polar particles (Rappsilber et al., 2003). As part of the LC-MS instrumentation, 
the Easy nano-flow high-performance liquid chromatography (HPLC) system (Thermo Fisher 
Scientific, Waltham, MA, USA) was used for the separation of the peptides. The samples (2 
µg) were loaded with buffer A (0.5% formic acid) onto 50 cm C18 columns and eluted with a 
280 min linear gradient from 2-30% buffer B (80% acetonitrile, 0.5% formic acid). Mass 
spectra were acquired in the Orbitrap analyzer with tandem mass spectrometry (Thermo Fisher 
Scientific). This set-up allows for the detection of the ionized molecules during the first stage 
and the measurement of the mass/charge (m/z) ratio of the fragmented molecules following 
high-energy collision dissociation (HCD) in the second stage (Fig. 5). The analysis of HCD 
peptide fragments facilitates the identification of proteins and peptides, as the breaking points 
of individual molecules are predictable or known, and therefore allows for easier matching of 
the results with protein databases. We furthermore matched the data from skeletal muscle to 
data from cultured differentiated mouse C2C12 myoblasts, which improved the peptide 
identification and increased the depth of the analyzed proteome by ~25%. 
3.3.4 Lipidomics of skeletal muscle tissue 
Similar to the assessment of the proteome of a cell, tissue or organism, the metabolome can 
be investigated using mass spectrometry. As a subset of metabolites, the different lipid species 
(Fig. 6, (Roberts et al., 2008)) in a sample can be identified and ratios between them can be 
established to give insight into metabolic alterations directly linked to lipid utilization or 
molecular signaling. In paper I, lipidomic analysis was performed on gastrocnemius muscle of 
4-hour-fasted high-fat diet fed DGKε KO and wildtype mice. The tissue samples were 
mechanically disrupted and lipids were extracted using chloroform and methanol (Folch et al., 
Figure 5: Liquid chromatography-mass spectrometry workflow. The peptides are separated on HPLC 




1957). Following centrifugation, the lipid-containing bottom phase was treated with isopropyl 
alcohol:methanol and 20 mM of ammonium acetate before the sample was administered into 
the infusion stream of a 5600 QQ Tof mass spectrometer (Sciex, Framingham, MA, USA) in 
electrospray mode at a flow rate of 20 ml/min. The sample was spiked with a series of internal 
saturated lipid standards which were used for normalization, resulting in a height ratio output. 
The internal standards used were C15:0 DAG, D5 tripalmitin, C14:0 phosphatidylcholines 
(PCs), C17:0 sphingomyelin, C17:0 ceramide, C15:0 lysophosphatidylcholines, and C15:0 
phosphatidylethanolamine (PE). 
3.4 STATISTICS 
3.4.1 Paper I, II and III 
All data are presented as mean ± SEM. Differences were determined by Student’s t-test or 
two-way ANOVA where applicable followed by Bonferroni’s post hoc test. Differences were 
considered statistically significant at p<0.05. Statistical analyses were performed using 
GraphPad Prism 7 (GraphPad Software Inc., CA). 
3.4.2 Paper IV 
For the global bioinformatics analysis, two sample t-tests were performed on Lean and Ob 
(ob/ob) groups with FDR=0.05 and S0=0.1. Hierarchical clustering of significantly different 
proteins was performed after Z-score normalization. Fisher’s exact tests were performed on 
Figure 6: Summary of the structural diversity of the most commonly analyzed lipid species. From Roberts 
et al., “A matter of fat: An introduction to lipidomic profiling methods”, 2008. Used with permission from Elsevier. 
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particular clusters, testing for enrichment or depletion of any annotation term in the cluster 
compared to the whole matrix. For the assessment of total protein abundance in the proteomics 
dataset and the Western blot analysis, differences between Lean and Ob were determined by 
Student’s t-test, with significance at p<0.05. Results are presented as median ± SD for the 
proteomics data and as mean ± SD for the Western blots. 
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4 SUMMARY OF THE MAIN FINDINGS 
Paper I 
Whole-body ablation of DGKε in mice elevated saturated and unsaturated DAG species in 
skeletal muscle without affecting liver triglyceride levels, body weight or body composition. 
Whole-body RER was decreased under high-fat fed conditions, indicating increased reliance 
on lipids as fuel source, yet whole-body glucose tolerance was increased albeit unchanged 
insulin-stimulated skeletal muscle glucose transport. These results support the notion that 
DGKε plays a role in modulating lipid metabolism in skeletal muscle affecting whole-body 
energy homeostasis. 
Paper II 
The skeletal muscle-specific overexpression of AMPKγ1H151R altered whole-body 
metabolic homeostasis with increased RER and insulin sensitivity, as well as altered energy 
expenditure. Several sex-specific effects were noted such as the reduction of perigonadal white 
adipose tissue mass and serum leptin in female AMPKγ1H151R mice. Together these findings 
suggest that the activation of AMPKγ1 specifically in skeletal muscle alters metabolic 
homeostasis favoring glucose utilization and may protect against the development of insulin 
resistance. 
Paper III 
The assessment of whole-body lipid oxidation with an in vivo assay relying on the 
intravenous administration of [9,10-3H(N)]-palmitic acid combined with the non-β-oxidizable 
palmitate analogue [1-14C]-2-bromopalmitic acid showed no differences between skeletal 
muscle-transgenic AMPKγ3R225Q and wildtype mice. However, the suppression of 
mitochondrial lipid oxidation by the CPT1 inhibitor etomoxir and an overall increase of whole-
body lipid oxidation under high-fat fed conditions were detected. 
Paper IV 
Analyzing skeletal muscle from obese and leptin-deficient ob/ob mice with an efficient 
state-of-the-art proteomics workflow led to the identification of over 6,000 proteins of which 
118 were differentially abundant in comparison to lean mice. Enzymes involved in lipid 
metabolism, proteins characteristic for oxidative type I fibers and mitochondrial, as well as 
peroxisomal, proteins were upregulated in quadriceps muscle from ob/ob mice together 
indicating increased fatty acid oxidation. 
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5 RESULTS AND DISCUSSION 
5.1 ROLE OF DGK IN THE REGULATION OF WHOLE-BODY METABOLISM 
DGKε is a member of a family of diacylglycerol kinases that catalyze the conversion of 
diacylglycerol into phosphatidic acid and thereby constitute a regulatory hub in DAG signaling, 
as well as lipid metabolism. DGKε is the only DGK isoform showing substrate specificity for 
DAGs with arachidonoyl acyl chains and plays a distinct role in enriching inositol 
phospholipids with unsaturated and saturated fatty acids. In paper I, we investigated the effect 
of the whole-body deletion of DGKε in mice on the regulation of energy homeostasis in relation 
to diet-induced obesity and insulin resistance with special focus on skeletal muscle.  
5.1.1 DGKε deficiency increases DAG species, glucose tolerance and lipid 
oxidation 
We provide evidence that the loss of DGKε alters the lipid profile of skeletal muscle as seen 
in the accumulation of unsaturated and saturated DAGs, as well as short-acyl-chain 
triglycerides (Fig. 7). This was expected and in line with previous research focusing on the 
effect the loss of other DGK isoforms, such as DGKδ, has on metabolic homeostasis (Chibalin 
et al., 2008). Paradoxically, the elevation of DAGs seen in high-fat fed DGKε KO mice was 
associated with increased reliance on lipids as fuel source as well as overall enhanced glucose 
tolerance (Fig. 8). This indicates that although DGKε expression was found to be reduced in 
skeletal muscle and adipose tissue of obese and insulin resistant ob/ob mice (Manneras-Holm 
et al., 2015), the complete loss of DGKε, in turn, does not appear to contribute to the metabolic 
disturbances associated with obesity and insulin resistance. However, our study does not 
address the effect a transient reduction of DGKε expression, possibly occurring with increasing 
obesity may have. Moreover, we cannot exclude the possibility that an acute deletion of DGKε 
may also affect metabolic parameters differentially. The comparison with a model of acute 
DGKε deletion via a tamoxifen-dependent knockout would give further insight into the role of 
DGKε in the development of metabolic diseases.  
High-fat fed DGKε KO mice exhibited increased abundance of mitochondrial enzymes in 
skeletal muscle concomitant with the changes in whole-body glucose and lipid metabolism. 
However, insulin sensitivity was unchanged in isolated skeletal muscle pointing towards the 
involvement of other tissues regulating whole-body metabolism. To further investigate the 
effect of DGKε deficiency on glucose metabolism, we performed a preliminary experiment to 
assess whole-body glucose uptake using a hyperinsulinemic-euglycemic clamp in high-fat fed 
male DGKε KO mice (Mannerås-Holm et al., unpublished). Hepatic glucose production was 
unchanged in DGKε KO mice, indicating that tissues other than the liver, possibly adipose 
tissue, may be involved. Additional studies focusing on the glucose uptake and regulation of 
metabolic homeostasis by adipose tissue, also with regard to lipolytic activity, in DGKε KO 
mice may answer these remaining questions. Together, the data presented in this study suggest 
that DGKε deficiency leads to an overall increase in fatty acid oxidation capacity and lipid 
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turnover, but the characterization of the specific effect on de novo lipid synthesis and glycerol 
metabolism, for example by using radioactively labelled substrates, requires further analyses.  
5.1.2 Skeletal muscle of DGKε deficient mice exhibits the “athlete’s paradox” 
The results of increased DAGs in skeletal muscle paired with elevated glucose tolerance are 
not consistent with the notion that skeletal muscle lipid accumulation is linked to insulin 
resistance. However, they reflect the “athlete’s paradox” where high oxidative capacity in 
skeletal muscle of well-trained athletes is paired with the accumulation of intracellular lipids 
without negatively impacting insulin sensitivity (Goodpaster et al., 2001). The change of the 
activity of a DGK isoform associated with a distinct subcellular region may alter the subcellular 
localization and accessibility of certain lipids in lipid droplets and hence modulate lipid 
Figure 7: Impact of DGKε on DAG levels in skeletal muscle. Gastrocnemius muscle was obtained from high- 
fat fed WT mice (open bars) and DGKε KO mice (solid bars) for lipidomics analysis of unsaturated (A) and 
saturated (B) DAG species. *p < 0.05. Refers to Fig. 1 in paper I. 
 24 
metabolism and partitioning. Athletes receiving a continuous lipid infusion concurrent with a 
hyperinsulinemic-euglycemic clamp, to inhibit lipolysis, showed not only an accumulation of 
intramuscular lipids specifically in type I fibers, but also a redistribution of perilipin (PLIN) 
proteins to newly formed lipid droplets, which was not observed in sedentary subjects 
(Shepherd et al., 2017, Townsend and McKie, 2017). One of the PLIN isoforms found in these 
newly formed droplets was PLIN2, which is directly linked to triglyceride synthesis via its 
association with diacylglycerol acyltransferase 2 (DGAT2), the enzyme catalyzing the 
conversion of DAGs into triglycerides (McIntosh et al., 2012). This draws further attention to 
the regulation of lipid metabolism by lipid droplet biochemistry, and could possibly help 
explain the physiological effects seen in animal models with altered DGK activity.  
5.1.3 Distinct metabolic changes following the loss of other DGK isoforms 
The ablation of DGKζ, another isoform highly abundant in skeletal muscle, leads to modest 
growth retardation and reduced adiposity indicating a function of this DGK family member 
during growth and development. Similar to DGKε KO mice, high-fat fed DGKζ KO mice are 
protected against insulin resistance despite increased DAG content in skeletal muscle 
(Benziane et al., 2017). Conversely, the loss of DGKα causes mild insulin resistance in chow-
fed mice, which is reversed after long-term high-fat feeding. Since DGKα, together with 
DGKζ, is the predominant DGK isoform found in T-cells, it plays a role in modulating 
inflammatory responses. Indeed, the expression of inflammatory markers was modestly 
increased in adipose tissue of short-term high-fat fed DGKα KO mice (Nascimento et al., 
2017). Together, these studies suggest that the ablation of either DGKα, ε or ζ causes relatively 
mild metabolic alterations in comparison to the detrimental effects of DGKδ haploinsufficiency 
on insulin sensitivity and metabolic flexibility (Chibalin et al., 2008). Interestingly, 
concomitant with impaired lipid oxidation, AMPK activation and signaling was reduced in 
skeletal muscle of DGKδ heterozygous mice (Jiang et al., 2016). Further studies focusing on 
the tissue-specific role of DGKδ in skeletal muscle and adipose tissue are warranted to 
Figure 8: DGKε deficiency enhances glucose tolerance and alters energy homeostasis. Intraperitoneal GTT 
was performed in 4 h fasted high-fat fed WT mice (open triangle; n = 14) and DGKε KO mice (solid triangle; n = 
11) as well as chow fed WT mice (open circle; n = 11) and DGKε KO mice (solid square; n = 12) (A). RER was 
assessed by indirect calorimetry in high-fat fed WT mice (open bar; n = 11) and DGKε KO mice (solid bar; n = 
10). Results are presented as the mean ± SEM. *P < 0.05. **P < 0.01 WT versus KO mice (Student t-test). Refers 
to Fig. 3/5 in paper I. 
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investigate whether site-specific activation of DGKδ constitutes a target for the treatment of 
insulin resistance.  
5.2 IMPACT OF ACTIVATING AMPKγ MUTATIONS IN SKELETAL MUSCLE ON 
METABOLISM 
The γ-subunit of AMPK regulates the activity and function of the heterotrimeric enzyme 
complex that acts as an energy sensor and modulator of cellular metabolism to match the energy 
demand within the cell. In paper II, we investigated the role of AMPKγ1 in the regulation of 
skeletal muscle and whole-body metabolism by overexpressing the mutated isoform 
AMPKγ1H151R specifically in skeletal muscle. In paper III, we assessed the impact of the 
skeletal muscle-specific expression of AMPKγ3R225Q on whole-body lipid metabolism with an 
in vivo assay relying on the infusion and oxidation of radioactively labelled lipids. 
5.2.1 AMPK activation in skeletal muscle increases glycogen storage and 
promotes whole-body carbohydrate metabolism 
We show that the expression of AMPKγ1H151R specifically in skeletal muscle improves 
whole-body insulin sensitivity and promotes glucose utilization while preserving the ability to 
switch between carbohydrates and lipids as fuel source (Fig. 9). Together with previously 
described models of mutations bypassing the need for AMP-binding to the AMPKγ subunit to 
activate the complex (Barnes et al., 2004, Barre et al., 2007), these data indicate that the main 
phenotypic effects described are probably not linked to particular γ-subunits, but most likely 
the result of a general activation of AMPK. Despite high levels of phosphorylated and hence 
inhibited glycogen synthase, all models of chronic AMPK activation show an accumulation of 
glycogen in skeletal muscle, arguably due to the overwriting stimulating effect increased 
glucose-6-phosphate concentration has on GS (Roach et al., 2012). Indeed, in skeletal muscle 
of pigs carrying an activating AMPK mutation (AMPKγ3R200Q), glucose-6-phosphate was 
reported to induce GS activity to a greater extent than in wildtype pigs (Scheffler et al., 2016). 
Interestingly, glycogen accumulation was preserved in pigs with an additional mutation 
affecting the gene of the ryanodine receptor 1 (RyR1R615C) that reportedly blocks AMPK-
induced GLUT4 expression via elevating cytosolic calcium (Park et al., 2009). The authors 
connect this to an increased expression of UDP-glucose phosphorylase 2 in skeletal muscle of 
pigs carrying the AMPKγ3R200Q mutation that possibly shuttles more glucose towards glycogen 
synthesis (Scheffler et al., 2016). However, we report increased glucose oxidation in 
AMPKγ1H151R transgenic mice, as indicated by a higher RER, despite robust inhibition of ACC 
in skeletal muscle and hence stimulation of fatty acid oxidation (Fig. 9). We conclude that these 
molecular changes, allowing for an elevated rate of glucose and lipid oxidation, support 
increased metabolic flexibility in a system constantly challenged to meet a high energy demand. 
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5.2.2 Sex-specific metabolic effects caused by the expression of AMPKγ1H151R 
in skeletal muscle 
Sex-specific differences are frequently observed in physiological, pharmaceutical and 
behavioral studies in humans and animals. The further elucidation of metabolic differences and 
the underlying differences is important for the improvement of treatment strategies for wide-
spread diseases like obesity and diabetes in both men and women. Here we are the first to 
describe sex-specific effects of skeletal muscle-specific AMPK activation. Although total body 
weight was unchanged in both male and female AMPKγ1H151R mice, males showed increased 
food intake while female mice had smaller perigonadal adipose tissue depots and reduced 
serum leptin and insulin levels (Fig. 10). Additionally, UCP1 mRNA in BAT and β3-adrenergic 
receptor mRNA in WAT was elevated in female AMPKγ1H151R mice suggesting a direct 
connection between skeletal muscle AMPK activity and the regulation of adipose tissue 
metabolism. Skeletal muscle of men and women responds differently to exercise as 
submaximal exercise strongly induces the phosphorylation of AMPKα in skeletal muscle of 
men, but not in women (Roepstorff et al., 2006). This difference may be due to a better 
maintenance of the cellular energy balance in skeletal muscle of women. In addition, a higher 
percentage of myosin heavy chain I fibers was found in skeletal muscle of women compared 
to men, possibly explaining the higher rate of lipid oxidation observed during exercise in 
women (Guadalupe-Grau et al., 2016). At rest, however, the female mice in our study 
predominantly oxidized glucose similarly to male mice. These findings indicate that the activity 
of AMPK in skeletal muscle mediates sex-specific effects on other tissues and the whole body. 
Figure 9: Skeletal muscle AMPKγ1H151R expression promotes whole-body glucose utilization and preserves 
metabolic flexibility. Whole-body glucose utilization was assessed in conscious 17-week-old male and female 
Wt (open bars) and AMPKγ1H151R transgenic mice (black bars) at basal and clamped states (n=3-8) (A). Respiratory 
exchange ratio (RER) was measured in male and female Wt and AMPKγ1H151R transgenic mice (16 –22 weeks of 
age) for 2 consecutive days (B) and one overnight (12 hours) fast (n=6-8) (C). Results are means ± SEM. *P ≤ 
0.05 and ***P ≤ 0.001 vs. respective Wt mice. Refers to Fig. 9/6 of paper II. 
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A direct binding of the estrogen receptor to AMPKα, resulting in the activation of the 
enzyme complex, was reported from cell-based studies (Lipovka et al., 2015). By utilizing 
ovariectomized mice lacking estrogen, the extent to which this mode of activation contributes 
to whole-body metabolic regulation in AMPKγ1H151R mutant mice may be examined. 
Additionally, quantification of serum adipokines such as adiponectin, which is inversely 
correlated to obesity and insulin resistance, could give further insight into the AMPK-related 
connection between skeletal muscle and adipose tissue metabolism observed in AMPKγ1H151R 
mice. Although women have higher plasma adiponectin, an association with leg glucose uptake 
and AMPK phosphorylation in skeletal muscle is only evident in men (Hoeg et al., 2013). This 
has again been linked to the sex-specific differences in skeletal muscle fibers as women have 
relatively less adiponectin receptor-expressing type II fibers (Bauche et al., 2007). In summary, 
the phenotypic effects observed in female AMPKγ1H151R mice that go beyond those seen in 
male mice are possibly associated with a greater impact of chronic AMPK activation in skeletal 
muscle of female versus male mice. This may be a plausible explanation given that female mice 
usually exhibit only moderate changes of AMPK activity due to a tighter regulation of energy 
balance. The effect of skeletal muscle-specific AMPKγ1H151R expression on gene expression 
in different adipose tissue depots is contradictory to the reduced energy expenditure detected 
in these mice. Thus, characterization of the primary metabolic link or secondary connection of 
these tissues via adipokines or myokines warrants further studies to elucidate the underlying 
mechanisms.  
Figure 10: Sex-specific effects of skeletal muscle AMPKγ1H151R expression. Food intake was measured for 2 
consecutive days in male and female Wt (open bars) and AMPKγ1H151R transgenic mice (black bars) (16 –22 weeks 
of age) housed in metabolic cages (n=3-8) (A). Gonadal fat pad weight of 4-h-fasted male and female Wt and 
AMPKγ1H151R transgenic mice (22 weeks of age) was measured after tissue dissection (n=6-9) (B). Serum leptin 
was measured in the same mice (C). Results are shown means ± SE. *P ≤ 0.05. Refers to Fig. 5/7 of paper II. 
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5.2.3 Skeletal muscle-specific activation of AMPKγ3 does not impact whole-
body lipid oxidation 
To allow for the in vivo assessment of whole-body fatty acid oxidation in conscious mice, 
we adapted and modified a technique that has previously only been used in rat studies (Oakes 
et al., 1999). The method relies on the intravenous administration of 3H-palmitic acid combined 
with a non-β-oxidizable palmitate analogue, 14C-2-bromopalmitate. The β-oxidation product, 
3H2O, accumulates in blood and peripheral tissues following the infusion of the tracers. Thus, 
it functions as a proxy for the oxidation rate, while the presence of 14C-2-bromopalmitate in the 
tissue represents lipid uptake. We validated the reliable quantification of whole-body fatty acid 
oxidation by pre-treating wildtype mice with etomoxir. The resulting blockage of CPT1-
mediated transport of lipids into the mitochondria led to a robust decrease of whole-body lipid 
oxidation without altering the overall clearance of 14C-bromopalmitate from the blood, despite 
decreased uptake by the oxidative tissues heart and soleus (Fig. 11). In addition to the inhibitory 
effect of etomoxir on lipid oxidation, additional studies to assess pharmacological compounds 
that induce whole-body lipid oxidation in lean mice would add a valuable positive control for 
the functionality of the assay.  
The recently described compound yhhu981 was shown to induce fatty acid oxidation in an 
AMPK-dependent manner in cell culture and to reduce RER in acutely treated ob/ob mice 
(Zeng et al., 2015). Although the impact of acute yhhu981-treatment on blood glucose was not 
reported, this compound could potentially provide further validation of the method presented 
in this study. Nevertheless, the time point for yhhu981 administration would likely have to be 
earlier than for etomoxir due to different pharmacodynamics. However, the chronic induction 
of AMPK activity in skeletal muscle of AMPKγ3R225Q mice did not alter the rate of whole-
body fatty acid oxidation. Although the oleate oxidation was increased in isolated EDL of high-
fat fed AMPKγ3R225Q mice (Barnes et al., 2004), the contribution of other tissues to whole-
body fatty acid oxidation may overwrite the mild effects of AMPKγ3 activation in skeletal 
muscle. In particular, investigating the contribution of lipid oxidation in BAT would be of 
interest as this adipose tissue depot quickly responds to metabolic alterations. Chronic 
pharmacological β3-adrenergic stimulation of rats fed a high-fat diet increased fatty acid 
Figure 11: Validation of the technical approach to measuring fatty acid oxidation rate in vivo. Rate of whole-
body fatty acid oxidation of saline (black bars) and etomoxir treated (open bars) mice (A). Clearance of 14C-2-
bromopalmitate from the blood of saline (black circles) and etomoxir-treated (open squares) mice (B). Tissue-
specific uptake of non-β-oxidizable 14C-2-bromopalmitate of saline- or etomoxir-treated mice (C). Results are 
shown as mean ± SEM, *p < 0.05. n=7 mice. Refers to Fig. 2 of paper III. 
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utilization of BAT to a level that exceeded that of heart and liver (Warner et al., 2016). This 
finding illustrates the potential impact of BAT activity on whole-body lipid utilization. Future 
studies to investigate the impact of skeletal muscle AMPK activity on whole-body fatty acid 
oxidation driven by BAT could further elucidate the sex-specific effects observed in female 
AMPKγ1H151R mice. Regardless of genotype, HFD consistently elevated whole-body fatty acid 
oxidation in vivo (Table 2). This is consistent with findings from previous studies in high-fat 
fed rodents focusing on fatty acid metabolism in liver and skeletal muscle (Turner et al., 2007, 
Ciapaite et al., 2011). However, the effect of long standing obesity and T2D on the oxidative 
capacity of human skeletal muscle and the potential value of therapeutically targeting it is still 
a matter of debate. 
 
 
FAO rate (nmol g-1 min-1) 
WT AMPKγ3R225Q 
Chow 4.00 ± 0.55 3.25 ± 0.30 
HFD # 6.71 ± 0.72 5.58 ± 0.82 
Table 2: #p < 0.05 Effect of chow or high-fat diet (HFD) on the rate of fatty acid oxidation as determined by 2-
way ANOVA. Results are shown as mean ± SEM. n=5-10. Refers to Table 2 in paper III. 
5.3 OBESITY PROMOTES ADAPTIVE CHANGES OF THE PROTEOME OF 
SKELETAL MUSCLE    
Using a newly adapted proteomics workflow on skeletal muscle from leptin-deficient, obese 
and insulin resistant ob/ob mice we identified 118 differentially regulated proteins associated 
with obesity and insulin resistance (paper IV). By matching the proteomics results from 
quadriceps skeletal muscle to peptides and proteins detected in C2C12 myotubes, over 6,000 
proteins could be identified in skeletal muscle including proteins involved in glucose and lipid 
metabolism, fiber type associated proteins and several secreted factors.  
5.3.1 Identification of proteins involved in inter-organ crosstalk with deep 
proteomics 
Exercise increases the secretion of multiple myokines that positively impact metabolic 
health (Febbraio and Pedersen, 2005). Nevertheless, the effect of obesity on the reduction of 
these myokines and the possible increased expression and secretion of others is incompletely 
understood (Oh et al., 2016). Further characterization of the inter-organ communication, 
especially between skeletal muscle and adipose tissue, and their dysregulation in the state of 
obesity and T2D could help identify new targets for the pharmacological treatment of metabolic 
diseases (Stanford and Goodyear, 2017). An analysis of the proteome of human adipose tissue 
has led to the identification of over 2,000 proteins showing differential abundance of proteins 
that are associated with age, sex and T2D (Gomez-Serrano et al., 2016). Such studies 
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underscore the value of deep proteomics techniques that enable the detection of very lowly 
abundant or unknown proteins in complex tissues such as skeletal muscle or adipose tissue. 
The here presented technical approach combining multiple enzyme digest filter-aided protein 
separation and MS-based peptide identification within two fractions over a relatively short 
reading time, in addition to the computational integration of the findings with results from cell 
culture models, constitutes another step towards the goal of mapping the entire proteome of 
cells, tissues and organisms.  
5.3.2 Elevated peroxisomal and mitochondrial proteins in skeletal muscle of 
leptin-deficient mice 
We observed an overall increase of mitochondrial proteins associated with lipid oxidation 
and an increased abundance of proteins characteristic of oxidative slow muscle fibers in 
skeletal muscle of ob/ob mice (Fig. 12). Additionally, elevated levels of proteins associated 
either with peroxisomes or with peroxisomes and mitochondria were detected, suggesting 
increased lipid fluxes and a concomitant elevation of cellular stress. Proteomics studies of 
skeletal muscle from obese men and women, on the other hand, showed reduced abundance of 
mitochondrial proteins and increased abundance of glycolytic proteins in obesity (Hittel et al., 
2005, Hwang et al., 2010). These findings raise the question of whether human and rodent 
muscle responds differently to metabolic challenges such as increased availability of free fatty 
acids (FFA) or if different stages of disease progression can explain the differences. The general 
comparability of mitochondrial function between human and mouse muscle has been 
confirmed for quadriceps muscle of young, healthy mice and humans (Jacobs et al., 2013). 
Nonetheless, a comparison of our findings generated using a genetic model of obesity due to 
complete leptin deficiency to a model of diet induced obesity, which would arguably better 
reflect human obesity and the associated metabolic perturbations, would be of interest. 
 
Figure 12: Enrichment of proteins associated with mitochondria and slow-twitch fibers in skeletal muscle 
of leptin-deficient ob/ob (Ob) mice. (A) Abundance of proteins associated with lipid transport, CoA acylation, 
carnitine shuttling and mitochondrial ß-oxidation in the proteome of quadriceps muscle of lean (black bars) and 
Ob mice (grey bars). Results are median ± SD, (n=4). (B) Western blot analysis of Myh7.Results are mean ± SD, 
(n=8). *p ≤ 0.05. Refers to Fig. 3/5 of paper IV. 
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5.3.3 Regulation of whole-body metabolic homeostasis by leptin and AMPK 
We detected elevated levels of phosphorylated AMPKαThr172 and ACCα/βSer79 in skeletal 
muscle of leptin-deficient mice, which is consistent with the notion of increased lipid oxidation. 
Interestingly, the administration of leptin also promotes skeletal muscle fatty acid oxidation via 
AMPK activation and ACC inhibition (Minokoshi et al., 2002, Wolsk et al., 2011, O'Neill et 
al., 2014). In obese men, however, the expression of leptin receptors in skeletal muscle was 
downregulated, possibly indicating that direct effects of leptin on skeletal muscle are hampered 
in human obesity (Fuentes et al., 2010). In mice, the increased availability of free fatty acids in 
hyperphagic obesity may possibly stimulate lipid oxidation even in a state of complete leptin 
deficiency. In addition to direct peripheral effects of leptin, central leptin administration was 
found to stimulate AMPK activity, PGC-1α expression and glucose uptake in skeletal muscle 
via the hypothalamic-sympathetic nervous system axis in a PI 3-kinase-dependent manner 
(Roman et al., 2010). However, the effect of leptin on skeletal muscle glucose uptake appears 
to be AMPK independent, as it is conserved in mice expressing a dominant negative form of 
AMPK in skeletal muscle (AMPKα1D157A) but appears to require intact β2-adrenergic signaling 
instead (Shiuchi et al., 2017). Indeed, increased AMPK activity in skeletal muscle of 
AMPKγ3R225Q mice was not sufficient to ameliorate insulin-resistance and obesity caused by 
leptin deficiency (Zachariah Tom et al., 2014). Further studies could elucidate the extent to 
which the reduced plasma leptin level detected in female AMPKγ1H151R mice is directly 
involved in the regulation of glucose and lipid metabolism in liver or adipose tissue. Leptin 
pre-treatment of brown adipocytes diminishes insulin-induced glucose uptake indicating that 
reduced exposure to leptin could increase BAT insulin action and have positive implications 
for the regulation of energy homeostasis (Kraus et al., 2002). Together, our findings further 
support the notion of a mechanistic connection between leptin action and AMPK activity in 
skeletal muscle in relation to whole-body energy metabolism.   
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6 CONCLUSION AND FUTURE PERSPECTIVE 
The rapidly increasing burden of obesity and associated metabolic diseases such as type 2 
diabetes on modern society underscores the need for a better understanding of the molecular 
processes impacting the regulation of glucose and lipid metabolism in cells, tissues and the 
whole body. Skeletal muscle, with its normally wide range metabolic flexibility, is a prominent 
target for therapeutic approaches aiming to improve metabolic health. The aim of this thesis 
was to further elucidate the role of skeletal muscle AMPK and DGK, two enzymes that 
constitute important signaling hubs in glucose and lipid metabolism, in the regulation of whole-
body energy homeostasis. Additionally, by utilizing a state-of-the-art technological approach, 
the aim was to characterize and understand the extent to which the skeletal muscle proteome is 
altered in the state of extreme obesity, with a particular focus on proteins involved in energy 
handling. 
We found that the ablation of DGKε caused an elevation of DAGs in skeletal muscle of 
diet-induced obese mice while concomitantly enhancing whole-body glucose tolerance and 
increasing the relative lipid oxidation rate. This effect was possibly due to an overall increase 
of lipid fluxes, thereby preventing lipotoxicity. However, skeletal muscle and hepatic insulin 
sensitivity were unchanged pointing towards enhanced insulin sensitivity of other tissues that 
have yet to be identified. Together with previous data demonstrating moderate physiological 
changes upon the loss of DGKα, favorable metabolic effects following the loss of DGKζ and 
the detrimental metabolic impact of the loss of DGKδ, our results indicate that different DGK 
isoforms play distinct roles in skeletal muscle and whole-body lipid and glucose metabolism. 
Further studies should identify the therapeutic value of isoform-specific modulations of DGK 
activity, for example by identifying or designing DGKδ activators and DGKε inhibitors, 
potentially even in a tissue-specific manner. 
Overexpressing AMPKγ1H151R in skeletal muscle bypassed the necessary activation of the 
AMPK complex through low cellular energy levels and led to improvements in insulin 
sensitivity and increased carbohydrate metabolism. Overall our results suggest that AMPK 
activation provides a potential protection against the development of insulin resistance. Future 
studies should evaluate whether this effect is preserved in obesity. Male mice expressing this 
activated form of AMPK were more active and showed an increased energy expenditure. 
Female mice showed a reduction of perigonadal WAT mass and leptin levels, as well as altered 
adipose tissue gene expression, possibly pointing towards increased BAT activity. Identifying 
the mechanism involved in the possible regulation of adipose tissue activity by skeletal muscle 
AMPK activation would be of great interest to further characterize the tissue crosstalk and its 
impact on whole-body energy metabolism. This is particularly important with regard to acute 
exercise and exercise training where the activation of AMPK is associated with positive effects 
on the whole body. Remaining of interest is the development of isoform-specific AMPK 
activators for the treatment of metabolic disease. This may be achieved by modifying recently 
developed decently specific AMPK activating compounds. Our data also underline the 
importance of investigating the effects of metabolic interventions in males and females in pre-
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clinical and clinical studies given the sex differences observed in male and female mice 
expressing the AMPKγ1H151R transgene.   
By using a newly established in vivo approach for measuring whole-body fatty acid 
oxidation in mice, employing 3H-palmitate, we were able to determine that the skeletal-muscle 
specific expression of AMPKγ3R225Q does not alter the whole-body rate of lipid oxidation, 
despite enhanced palmitate oxidation in isolated glycolytic skeletal muscle. Thus, the effects 
of this mutation in skeletal muscle may be masked at the whole-body level, given the 
contribution of other tissue to the regulation of whole body metabolism. Thus, a more in-depth 
analysis of the contribution of a range of individual tissues to whole body lipid metabolism as 
assessed with this assay is warranted to provide a valuable resource for studies of metabolically 
active compounds and their systemic effects. The treatment of mice with the CPT1-inhibitor 
etomoxir, preventing lipid transport into mitochondria, consistently lowered the lipid oxidation 
rate providing a proof-of-concept. Interestingly, high-fat fed mice, independently of genotype, 
showed elevated oxidation rates compared to lean mice, arguing against impaired oxidative 
capacity in early obesity. Whether these changes in lipid oxidation are preserved at later stages 
in the course of obesity and the development of insulin resistance, or in states of excessive 
hepatic lipid accumulation, should be investigated in future studies.  
The characterization of changes in the skeletal muscle proteome in leptin-deficient obesity 
provides a valuable research resource for future studies on cause and treatment of skeletal 
muscle insulin resistance. Of note, the mitochondrial and peroxisomal proteins involved in 
glucose and lipid utilization, as well as the proteins involved in oxidative stress, that were 
differentially abundant in skeletal muscle of lean and obese mice should be in the focus of these 
future investigations. Further studies are also warranted to assess whether the observed effect 
of leptin deficiency and obesity on the skeletal muscle proteome of male mice is comparable 
to that of female mice, especially with regard to the fiber type abundance and the activity of 
AMPK. Overall, the preservation or loss of the oxidative capacity of skeletal muscle 
mitochondria appears to be determining in the development and progression of insulin 
resistance and type 2 diabetes. Additional insight into differentially expressed known or novel 
secreted factors would also be valuable to understand the underlying cause of skeletal muscle 
insulin resistance. This would also be of interest with regard to the identification of exercise-
mediated effects on the secretion of myokines in order to preserve insulin sensitivity. Here 
further optimization of proteomics applications is crucial to eventually allow for the 
measurement and identification of the complete proteome of a tissue and ideally in blood. 
Expecting that in the future, the time and cost of these analyses will be further reduced, these 
approaches may offer an invaluable tool in combination with other “omics” approaches for 
diagnostics of disease markers, the establishment of hallmarks of disease progression and 
personalized medicine. 
The regulatory network orchestrating metabolic processes in the cell consists of several 
hundred enzymes, including a plethora of kinases. By focusing on kinases involved in the 
regulation of skeletal muscle metabolism with effects on the whole body, the work presented 
here (Fig. 13) identifies possible targets for the prevention and treatment of metabolic diseases. 
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Figure 13: Schematic overview over the studies and main findings presented in this thesis. 
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7 ZUSAMMENFASSUNG 
Übergewicht und damit assozierte Krankheiten wie Typ-2-Diabetes nehmen weltweit stetig 
zu. Das Gleichgewicht zwischen Nahrungsaufnahme und Energieverbrauch im Körper 
unterliegt einer strengen Kontrolle und wird durch verschiedene Gewebe reguliert. 
Quergestreifte Muskulatur ist einer der Hauptakteure in diesem regulierenden System, z.B. 
weil sie je nach Angebot sowohl Zucker als auch Fett problemlos verstoffwechseln kann. Dies 
beeinflusst den Stoffwechsel des gesamten Körpers. Eine Vielzahl Hormone und Enzyme sind 
in diese Prozesse im Muskel eingebunden und die hier vorliegende Arbeit befasst sich mit 
einigen von ihnen. 
Das Enzym Diacylglycerinkinase (DGK) reguliert die Konzentration verschiedener Fette in 
der Zelle. Mehrere ähnliche Enzymvarianten gehören zu der DGK-Familie und wir haben 
untersucht, welche Rolle das Familienmitglied DGKε in der Regulierung des Stoffwechsels 
spielt. Das Ausschalten des DGKε-Gens in Mäusen führte zu einer Ansammlung bestimmter 
Fette in den Muskelzellen. Obwohl dies in der Regel mit Insulinresistenz assoziiert ist, z.b. bei 
starkem Übergewicht, waren die Mäuse in der Lage größere Mengen Zucker aus dem Blut in 
die Körpergewebe aufzunehmen. Interessanterweise bauten die Mäuse allerdings 
verhältnismäßig mehr Fett als Zucker ab im Vergleich zu Mäusen mit intaktem DGKε. 
Ingesamt zeigen diese Ergebnisse, dass DGKε sowohl Teil der Regulierung des 
Fettstoffwechsels im Muskel als auch des Gesamtstoffwechsels des Körpers ist. 
Die Aktivierung des aus drei Untereinheiten bestehenden Enzyms AMP-aktivierte 
Proteinkinase (AMPK) begünstigt die Herstellung des Energieträgers ATP in der Zelle in 
Phasen des erhöhten Energiebedarfs wie während des Sports. Die genetische Veränderung der 
AMPKγ1-Untereinheit im Muskel führte zur dauerhaften Aktivierung des Enzymkomplexes 
mit weitreichenden Folgen für den gesamten Körper. Die Empfindlichkeit sämtlicher Gewebe 
gegenüber Insulin war gesteigert und die Mäuse bauten insgesamt mehr Zucker ab. Speziell in 
Weibchen führte diese muskelspezifische Mutation darüberhinaus zu einer Verkleinerung der 
Bauchfettpolster. Diese Erkenntnisse unterstreichen den potentiellen therapeutischen Nutzen 
von Wirkstoffen, die AMPK direkt im Muskel stimulieren. Obwohl die muskelspezifische 
genetische Aktivierung von AMPKγ3 ebenfalls mit Veränderungen von 
Stoffwechselprozessen assoziert ist, begünstigte sie in unserer Studie keine verstärkte 
Verstoffwechselung von Fett. Mit einer neuen Methode, basierend auf der Verstoffwechselung 
von radioaktivem 3H-Palmitat und der anschließenden Quantifizierung des enstehenden 
Wassers (3H2O), konnten wir allerdings eine ingesamt erhöhte Fettstoffwechselrate in Mäusen 
auf einer fetthaltigen Diät feststellen. Ob eine fetthaltige Diät im Menschen die 
Fettstoffwechselrate allerdings tatsächlich erhöht oder eventuell sogar reduziert und damit eine 
weitere Gewichtszunahme begünstigt, ist weiterhin ungeklärt. 
Die Grundstruktur des Muskels verändert sich mit Übergewicht und die Herstellung von 
Proteinen passt sich sowohl an das gesteigerte Energieangebot als auch das erhöhte 
Körpergewicht an. Mithilfe einer auf Massenspektroskopie basierenden Methode konnten wir 
über 6000 Proteine des “Proteoms” (die Gesamtheit aller Proteine) in den Muskeln von 
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schlanken und stark übergewichtigen Mäusen denen das Sättigungshormon Leptin fehlt (sog. 
ob/ob Mäuse) identifizieren. 118 dieser Proteine kamen entweder häufiger oder weniger häufig 
in den Muskeln der dicken im Vergleich zu denen der schlanken Mäusen vor. Insbesondere die 
Menge an Enzymen die Teil des Fettstoffwechsels sind und an Proteinen charakteristisch für 
langsame Typ I Musklefasern war größer. Desweiteren kamen zahlreiche Proteine, die 
typischerweise in Mitochondrien und Peroxisomen vorkommen, vermehrt vor. Diese 
Zellorganellen spielen eine entscheidende Rolle im Zellstoffwechsel und der Abpufferung von 
Zellstress. Ingesamt zeigen auch diese Ergebnisse, dass chronisches Übergewicht, zumindest 
in Mäusen, sehr wahrscheinlich mit einer erhöhten Fettstoffwechselrate in den Muskeln einher 
geht. 
Zusammenfassend lässt sich sagen, dass sowohl die enzymatische Aktivität von DGKε als 
auch von AMPKγ1 and γ3 im Muskel Einfluss hat auf die Regulierung des Stoffwechsels des 
gesamten Körpers. Übergewicht verursacht weitreichende Veränderungen in diesem System 
und beinflusst die Herstellungsrate von bestimmten Proteinen, was möglicherweise die erhöhte 
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